We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
-23.39%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$275M
AUM Growth
-$31.9M
Cap. Flow
+$62.8M
Cap. Flow %
22.81%
Top 10 Hldgs %
72.23%
Holding
42
New
4
Increased
19
Reduced
4
Closed
8

Top Buys

1
INCY icon
Incyte
INCY
+$28.3M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$19.5M
3
BLUE
bluebird bio
BLUE
+$10.5M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$10.3M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$4.17M

Top Sells

1
OMER icon
Omeros
OMER
+$11.3M
2
DYAX
DYAX CORPORATION
DYAX
+$4.36M
3
KITE
Kite Pharma, Inc.
KITE
+$3.65M
4
ANIK icon
Anika Therapeutics
ANIK
+$1.05M
5
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$1.04M

Sector Composition

1 Healthcare 85.27%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
1
Alnylam Pharmaceuticals
ALNY
$37.1B
$54.4M 19.74%
866,379
+293,018
+51% +$19.5M
INCY icon
2
Incyte
INCY
$23.7B
$27.5M 9.98%
+379,415
New +$28.3M
LJPC
3
DELISTED
La Jolla Pharmaceutical Company
LJPC
$24.4M 8.87%
1,169,065
+84,649
+8% +$1.51M
ACHN
4
DELISTED
Achillion Pharmaceuticals
ACHN
$19.8M 7.17%
2,558,859
+569,945
+29% +$4.17M
KITE
5
DELISTED
Kite Pharma, Inc.
KITE
$15.8M 5.73%
343,503
-75,432
-18% -$3.65M
OMER icon
6
Omeros
OMER
$687M
$13.7M 4.97%
891,522
-927,819
-51% -$11.3M
AVXS
7
DELISTED
AveXis, Inc. Common Stock
AVXS
$12.9M 4.68%
+473,374
New +$10.3M
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$10.9M 3.94%
2,026,894
+14,232
+0.7% +$89.8K
AGEN
9
Agenus
AGEN
$207M
$10M 3.65%
123,020
+10,194
+9% +$687K
BLUE
10
DELISTED
bluebird bio
BLUE
$9.62M 3.49%
17,476
+17,067
+4,173% +$10.5M
FPRX
11
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$9.22M 3.35%
226,998
-30,238
-12% -$1.04M
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$9.17M 3.33%
428,457
+43,001
+11% +$962K
SSRG
13
DELISTED
SYMMETRY SURGICAL INC COMMON STK
SSRG
$9.07M 3.29%
919,680
+40,057
+5% +$376K
ATRA icon
14
Atara Biotherapeutics
ATRA
$77.6M
$9M 3.27%
18,925
+1,568
+9% +$706K
BMY icon
15
Bristol-Myers Squibb
BMY
$126B
$7.01M 2.54%
109,701
– –
BCRX icon
16
BioCryst Pharmaceuticals
BCRX
$2.34B
$5.59M 2.03%
1,973,932
-36,569
-2% -$162K
TLT icon
17
iShares 20+ Year Treasury Bond ETF
TLT
$42.2B
$3.92M 1.42%
+30,000
New +$3.84M
CLDX icon
18
Celldex Therapeutics
CLDX
$2.81B
$3.74M 1.36%
65,958
+23,475
+55% +$2.64M
CORI
19
DELISTED
Corium International, Inc.
CORI
$3.2M 1.16%
828,332
+84,467
+11% +$444K
GBT
20
DELISTED
Global Blood Therapeutics, Inc.
GBT
$3.03M 1.1%
190,981
+15,825
+9% +$281K
RGNX icon
21
Regenxbio
RGNX
$503M
$2.61M 0.95%
241,323
+19,997
+9% +$256K
LPCN icon
22
Lipocine
LPCN
$18.8M
$2.44M 0.89%
14,143
+1,172
+9% +$200K
AXDX
23
DELISTED
Accelerate Diagnostics
AXDX
$1.68M 0.61%
11,718
+971
+9% +$137K
IVTY
24
DELISTED
Invuity, Inc
IVTY
$1.54M 0.56%
212,808
+10,000
+5% +$77K
CYTR
25
DELISTED
CytRx Corp
CYTR
$1.38M 0.5%
85,515
+7,086
+9% +$96.8K
1
2

Similar funds

BEI
Benjamin Edwards Inc Clayton, Missouri $10.1B AUM 14.03% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return

RTW Investments's Q1 2016 Portfolio in Review

As of Q1 2016, RTW Investments held 42 positions worth $275M, down 10% from $307M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

RTW Investments deployed $62.8M of net new capital in Q1 2016, opening 4 new positions and adding to 19 existing holdings. Its largest new stake was Incyte: 379,415 shares worth $27.5M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 79% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Omeros, an estimated $11.3M trimmed.

  • RTW Investments's largest Q1 2016 buy was Incyte: 379,415 shares worth $27.5M.
  • RTW Investments added most to Alnylam Pharmaceuticals in Q1 2016, an estimated $19.5M increase.
  • RTW Investments's biggest Q1 2016 reduction was Omeros, cutting an estimated $11.3M.
  • RTW Investments fully exited DYAX CORPORATION in Q1 2016, selling an estimated $4.36M.
  • RTW Investments's ten largest holdings make up 72% of its $275M portfolio in Q1 2016.
  • RTW Investments opened 4 new positions and closed 8 in Q1 2016.
  • RTW Investments's portfolio value fell 10% quarter-over-quarter to $275M.

Based on RTW Investments's 13F filing for Q1 2016, filed 11 May 2016.